. home.aspx


New Alzheimer’s Vaccine May Show Promise.

September 04, 2019

Many biotechs have aimed to resolve Alzheimer’s via a vaccine over recent years, only to call it off due to nasty side effects such as brain swelling. But this drug, which the company has dubbed UB-311, is offering hope after wrapping up a Phase 2a Clinical Study. Next, the drug will begin a 2b study, which will further determine efficacy, before going on to a Phase 3 study if all is successful. Phase 3 is the necessary trial before drug approval and is tested on large groups of patients.